These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23878260)

  • 1. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation.
    Leppänen VM; Tvorogov D; Kisko K; Prota AE; Jeltsch M; Anisimov A; Markovic-Mueller S; Stuttfeld E; Goldie KN; Ballmer-Hofer K; Alitalo K
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12960-5. PubMed ID: 23878260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
    Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization.
    Brozzo MS; Bjelić S; Kisko K; Schleier T; Leppänen VM; Alitalo K; Winkler FK; Ballmer-Hofer K
    Blood; 2012 Feb; 119(7):1781-8. PubMed ID: 22207738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.
    Leppänen VM; Jeltsch M; Anisimov A; Tvorogov D; Aho K; Kalkkinen N; Toivanen P; Ylä-Herttuala S; Ballmer-Hofer K; Alitalo K
    Blood; 2011 Feb; 117(5):1507-15. PubMed ID: 21148085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A.
    Markovic-Mueller S; Stuttfeld E; Asthana M; Weinert T; Bliven S; Goldie KN; Kisko K; Capitani G; Ballmer-Hofer K
    Structure; 2017 Feb; 25(2):341-352. PubMed ID: 28111021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites.
    Hyde CA; Giese A; Stuttfeld E; Abram Saliba J; Villemagne D; Schleier T; Binz HK; Ballmer-Hofer K
    Mol Cell Biol; 2012 Oct; 32(19):3802-13. PubMed ID: 22801374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling.
    Thieltges KM; Avramovic D; Piscitelli CL; Markovic-Mueller S; Binz HK; Ballmer-Hofer K
    Angiogenesis; 2018 Aug; 21(3):533-543. PubMed ID: 29502220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
    Tvorogov D; Anisimov A; Zheng W; Leppänen VM; Tammela T; Laurinavicius S; Holnthoner W; Heloterä H; Holopainen T; Jeltsch M; Kalkkinen N; Lankinen H; Ojala PM; Alitalo K
    Cancer Cell; 2010 Dec; 18(6):630-40. PubMed ID: 21130043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands.
    Anisimov A; Leppänen VM; Tvorogov D; Zarkada G; Jeltsch M; Holopainen T; Kaijalainen S; Alitalo K
    Sci Signal; 2013 Jul; 6(282):ra52. PubMed ID: 23821770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites.
    Dixelius J; Makinen T; Wirzenius M; Karkkainen MJ; Wernstedt C; Alitalo K; Claesson-Welsh L
    J Biol Chem; 2003 Oct; 278(42):40973-9. PubMed ID: 12881528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
    Baldwin ME; Catimel B; Nice EC; Roufail S; Hall NE; Stenvers KL; Karkkainen MJ; Alitalo K; Stacker SA; Achen MG
    J Biol Chem; 2001 Jun; 276(22):19166-71. PubMed ID: 11279005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factors encoded by Orf virus show surprising sequence variation but have a conserved, functionally relevant structure.
    Mercer AA; Wise LM; Scagliarini A; McInnes CJ; Büttner M; Rziha HJ; McCaughan CA; Fleming SB; Ueda N; Nettleton PF
    J Gen Virol; 2002 Nov; 83(Pt 11):2845-2855. PubMed ID: 12388821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of VEGFR-1-binding domain of VEGF-A with modelled VEGF-C sheds light on receptor specificity.
    Kasap M; Sazci A
    J Theor Biol; 2008 Aug; 253(3):446-51. PubMed ID: 18479712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticalins directed against vascular endothelial growth factor receptor 3 (VEGFR-3) with picomolar affinities show potential for medical therapy and in vivo imaging.
    Richter A; Skerra A
    Biol Chem; 2017 Jan; 398(1):39-55. PubMed ID: 27458663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling.
    Yang Y; Xie P; Opatowsky Y; Schlessinger J
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1906-11. PubMed ID: 20080685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the interaction between endostatin short peptide and VEGF receptor 3.
    Han KY; Azar DT; Sabri A; Lee H; Jain S; Lee BS; Chang JH
    Protein Pept Lett; 2012 Sep; 19(9):969-74. PubMed ID: 22512651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
    Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
    J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.